Literature DB >> 11291061

Diverging breast cancer mortality rates in relation to screening? A comparison of Nijmegen to Arnhem and the Netherlands, 1969-1997.

M J Broeders1, P G Peer, H Straatman, L V Beex, J H Hendriks, R Holland, A L Verbeek.   

Abstract

Age-standardised breast cancer mortality rates have been stable for decades. However, rates have started to decline in several Western countries. In countries where population-based screening programmes for breast cancer were introduced in the late 1980s or early 1990s, the key question now is to what extent screening is responsible for the reported declines in mortality. This study compares breast cancer mortality rates in Nijmegen, where a screening programme for breast cancer was introduced in 1975, to a control city, Arnhem, and to the Netherlands as a whole over a 20-year period. Age-standardised breast cancer mortality rates as well as age-standardised mortality ratios were calculated for successive calendar years from 1969 to 1997. Further, a tailor-made period-cohort-group Poisson regression model was fitted. Figures displaying age-standardised mortality rates and ratios showed inconclusive patterns with regard to the expected impact of screening. Depending on when mortality rates were allowed to deviate between populations, the period-cohort-group analysis indicated a non-significant 6% to 16% reduction in breast cancer mortality after 2 decades in favour of the Nijmegen female population. Possible explanations are discussed as to why the mortality reductions reported by randomised trials might not be observed in a public health screening programme, such as the Nijmegen programme, evaluated by comparisons of geographical trends. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11291061     DOI: 10.1002/1097-0215(200102)9999:9999<::aid-ijc1186>3.0.co;2-b

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Mammography interval and breast cancer mortality in women over the age of 75.

Authors:  Michael S Simon; Sylvia Wassertheil-Smoller; Cynthia A Thomson; Roberta M Ray; F Allan Hubbell; Lawrence Lessin; Dorothy S Lane; Lew H Kuller
Journal:  Breast Cancer Res Treat       Date:  2014-09-25       Impact factor: 4.872

2.  Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database.

Authors:  Philippe Autier; Mathieu Boniol; Anna Gavin; Lars J Vatten
Journal:  BMJ       Date:  2011-07-28

3.  Observed and Predicted Risk of Breast Cancer Death in Randomized Trials on Breast Cancer Screening.

Authors:  Philippe Autier; Mathieu Boniol; Michel Smans; Richard Sullivan; Peter Boyle
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

4.  Effectiveness of and overdiagnosis from mammography screening in the Netherlands: population based study.

Authors:  Philippe Autier; Magali Boniol; Alice Koechlin; Cécile Pizot; Mathieu Boniol
Journal:  BMJ       Date:  2017-12-05

5.  Mammography service screening and breast cancer mortality in New Zealand: a National Cohort Study 1999-2011.

Authors:  Stephen Morrell; Richard Taylor; David Roder; Bridget Robson; Marli Gregory; Kirsty Craig
Journal:  Br J Cancer       Date:  2017-02-09       Impact factor: 7.640

6.  Breast cancer mortality trends in two areas of the province of Florence, Italy, where screening programmes started in the 1970s and 1990s.

Authors:  G Gorini; M Zappa; G Miccinesi; E Paci; A Seniori Costantini
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

7.  Screening mammography & breast cancer mortality: meta-analysis of quasi-experimental studies.

Authors:  Veronica L Irvin; Robert M Kaplan
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.